Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia

Male 0301 basic medicine Delayed Diagnosis Adolescent Interferon alpha-2 Antiviral Agents Polyethylene Glycols 03 medical and health sciences Ribavirin Humans Asymptomatic Infections Aged Aged, 80 and over R Interferon-alpha Pneumonia Middle Aged Recombinant Proteins 3. Good health Middle East Respiratory Syndrome Coronavirus Medicine Original Article Drug Therapy, Combination Female Coronavirus Infections Respiratory Insufficiency
DOI: 10.5144/0256-4947.2014.396 Publication Date: 2017-03-25T10:16:28Z
ABSTRACT
Middle Eastern respiratory syndrome caused by novel coronavirus (MERS CoV) has been a major public health challenge since it was first described in 2012 Saudi Arabia. So far, there is no effective treatment for this serious illness, which features high mortality rate. We report an initial experience of the use ribavirin and interferon (IFN)-a2b management MERS CoV at tertiary care hospital.A case series 6 patients admitted with confirmed diagnosis were treated IFN-a2b addition to supportive management. The patients' demographics, clinical parameters, outcomes recorded. Fifty-four close contacts these screened CoV.Six infection included study. Four cases featured symptomatic disease, including pneumonia failure, while 2 asymptomatic patients. reverse transcription-polymerase chain reaction detection consensus viral RNA targets upstream E gene (UPE) open reading frame (ORF1b) on sputum sample. comorbid conditions, time initiation treatment, recorded.Three out who had conditions died during study period, 3 suc.cessful outcomes. delayed average 15 days those died. Only 54 (3.7%) positive CoV.Treatment may be infected CoV. There appears low infectivity rate among
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (15)
CITATIONS (36)